Life Scientist > Life Sciences

Synchrotron pulls in $5m from ANSTO

01 July, 2004 by Melissa Trudinger

The Australian Synchrotron project has scored another AUD$5 million funding for the initial suite of beamlines from the Australian Nuclear Science and Technology Organisation (ANSTO), which joins the University of Melbourne, Monash University, CSIRO and MiniFAB as a foundation partner.


Sydney IVF produces stem cells

24 June, 2004 by Susan Williamson

Fertility clinic Sydney IVF has obtained stem cells from an Australian embryo, which it will make available to stem cell researchers.


Norwood Immunology aims to beat European IPO blues

24 June, 2004 by Renate Krelle

Norwood Abbey Ltd [ASX:NAL NASDAQ:NABYF] is close to snatching victory from the jaws of a hostile London investment market, announcing today that its subsidiary Norwood Immunology will list next Wednesday on London’s Alternative Investment Market (AIM), selling 15 million shares and raising AUD$15 million.


News: 300km/h on the wind superhighway

21 June, 2004 by Graeme O'Neill

How do plant pathogens proliferate? Graeme O'Neill finds that new research suggests the answer is blowin' in the wind.


NSCC, Stem Cell Sciences to team up on ES cell lines

07 June, 2004 by Melissa Trudinger

Stem Cell Sciences (SCS), the former Melbourne company now based in the UK, is to collaborate with Australia's National Stem Cell Centre on new human embryonic stem cell lines to be derived by SCS and Melbourne IVF.


News: Baby teeth could be rich stem cell source

02 June, 2004 by Graeme O'Neill

In future, the tooth fairy may leave children something more than a silver coin in a glass of water, in exchange for their lost milk teeth. Researchers at the Hanson Institute in Adelaide believe pluripotent stem cells from those deciduous teeth could help sustain their owners’ dental, skeletal, neural and cardiovascular health well into the autumn of their lives.


News: Using stem cells to grow organs organically

02 June, 2004 by Graeme O'Neill

Australian scientists believe it may be possible to grow replacement organs organically, by providing organ-building stem cells with a 3D template and leaving them to grow in situ, within the patient’s own body.


News: Researchers dig into Top End soil

02 June, 2004 by Susan Williamson

A team at CSIRO Tropical Ecosystems Research Centre in Darwin is getting an insight into how soil macro-invertebrates like termites, worms and ants help to maintain healthy country in the tropics.


Biocatalysis: the next molecular biology revolution

02 June, 2004 by Susan Williamson

The biocatalysis group at CSIRO Molecular Science, led by Prof Michael Zachariou, has established an impressive pipeline of research and is working towards developing a more sustainable and renewable chemical industry in Australia, writes Susan Williamson.


Beam me up: the Synchotron is on its way

27 May, 2004 by Melissa Trudinger

Medical researchers in Melbourne were given a brief glimpse this week of the potential of the synchrotron to enhance and expand medical science.


Renowned polymer chemist to join Bio21

10 May, 2004 by Melissa Trudinger

Expatriate Australian polymer chemist Prof Andrew Holmes is set to join Melbourne's Bio21 Institute of Molecular Science and Biotechnology in October.


Stem Cell Centre relieved by fed funding top-up

10 May, 2004 by Melissa Trudinger

The National Stem Cell Centre has received a substantial boost in the form of an extra AUD$55 million in federal government funding to support it through the period 2006-2011.


Further studies planned into J&J and Amgen anaemia drug risks

05 May, 2004 by Reuters

A US advisory panel has voiced support for further research to determine whether widely used anaemia drugs sold by Johnson & Johnson and Amgen might stimulate tumour growth.


Singapore's Cordlife sets up CyGenics, plans Australian capital raising

23 April, 2004 by Renate Krelle

Singapore-based Cordlife has created a holding company, CyGenics, which will be based in Melbourne, and revealed plans to raise up to $20 million in funding.


Select Vaccines aiming to raise $1.8m

20 April, 2004 by Melissa Trudinger

Select Vaccines (ASX:SLT) is planning to raise up to AUD$1.8 million in a private placement to support its R&D programs.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd